Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

Core Viewpoint - Nuwellis, Inc. is exiting international operations to focus exclusively on the U.S. market, where it is experiencing the strongest growth and clinical demand [1][2][3] Company Strategy - The strategic realignment supports Nuwellis' core business strategy of investing in markets that drive revenue growth, particularly in U.S. cardiac surgery and pediatric programs [2][3] - The company aims to streamline operations to prioritize investment in areas with immediate and long-term impact [2][3] Market Focus - Nuwellis is doubling down on the U.S. market, focusing on high-acuity and hospital-based outpatient settings [3] - Cardiac surgery, pediatrics, and outpatient models are identified as the strongest growth drivers, offering faster intervention and better patient outcomes [3] Operational Changes - The company will support its international partners through a structured wind-down period, aligning operations with market demand [4] - This shift emphasizes operational discipline and customer focus to deliver shareholder value [4] Product Information - Nuwellis is dedicated to transforming the lives of patients suffering from fluid overload through its Aquadex SmartFlow® system, which is indicated for ultrafiltration therapy [5][6] - The system is designed for both adult and pediatric patients and is administered in clinical settings under physician supervision [6]